Recombinant Human Growth hormone receptor (GHR)

What is the basic structure and function of the Growth Hormone Receptor (GHR)?

The growth hormone receptor (GHR) is a transmembrane protein embedded in the outer membrane of cells throughout the body. It consists of:

• An extracellular domain (ECD) containing two fibronectin type III (FNIII) homology domains

• A transmembrane domain (TMD)

• An intracellular domain (ICD) that associates with Janus kinase 2 (JAK2)

GHRs exist as preformed dimers on the cell surface before hormone binding, with the dimerization occurring in the endoplasmic reticulum. The receptor mediates growth hormone effects by activating JAK2 when growth hormone binds, initiating downstream signaling cascades .

Analysis using FRET techniques showed that the dimeric-GHR ICDs are positioned farther apart the greater the distance from the transmembrane domain, indicating a specific orientation in the inactive state .

How do the different isoforms of GHR affect r-hGH treatment response?

Two main isoforms of GHR have been identified:

• Full-length GHR (fl-GHR): Contains all exons

• d3-GHR: Missing exon 3

Studies examining these isoforms in growth disorders have shown variable results regarding treatment response:

• Some research indicates children with the d3-GHR isoform experience faster growth during r-hGH treatment compared to those with fl-GHR

• Other studies have not found significant differences in growth response

• The GHR exon 3 polymorphism has been specifically studied in Turner Syndrome to understand its influence on treatment efficacy

These conflicting findings highlight the complex relationship between GHR genetics and treatment outcomes, with methodological differences and small sample sizes contributing to inconsistent results across studies.

What mechanisms regulate GHR expression and availability on the cell surface?

GHR surface abundance is regulated through several mechanisms:

Biogenesis pathway:

• Synthesis in the endoplasmic reticulum

• Rapid dimerization as a high-mannose glycoprotein precursor

• Trafficking through the Golgi complex

• Acquisition of mature glycosylation

• Transport to the cell surface

Down-regulation mechanisms:

• Metalloprotease-mediated cleavage in the proximal extracellular domain, releasing the extracellular domain as a GH-binding protein

• Ligand-independent (constitutive) down-regulation via proteasomal and lysosomal pathways

• JAK2-dependent stabilization of mature GHR through interaction with the receptor's Box 1 element

Experimental evidence shows that JAK2 significantly enhances mature GHR stability (increasing half-life from ~1.5h to >4h), and this stabilization requires an intact FERM domain in JAK2 and Box 1 element in GHR .

How does GH binding activate the preformed GHR dimers?

Despite GHRs existing as preformed dimers, GH binding is required to activate signaling. The activation mechanism involves:

• GH binding to the receptor's "site 1" through high-affinity interactions

• Secondary binding to "site 2" on the second receptor

• Conformational changes rather than dimerization per se

Key findings include:

• Crystallographic studies comparing unliganded and ligand-bound GHR ECDs showed only a 7-9° rotation between upper and lower FNIII-type domains

• This rotation is small compared to conformational changes in receptor tyrosine kinases (RTKs)

• The relative positioning of receptor subunits rather than dimerization is critical for activation

Experimental evidence indicates that while antibodies could activate a hybrid GHR/G-CSFR receptor, only one out of eight antibodies showed weak agonist activity on full-length GHR, confirming that receptor dimerization alone is insufficient for activation .

What role does the transmembrane domain (TMD) play in GHR function?

Research using GHR mutants with altered TMDs has provided insights into its role:

• A GHR mutant (GHRLDLR) with the TMD replaced by the human low-density lipoprotein receptor TMD still supported receptor dimerization, indicating the GHR TMD is not essential for dimerization

• The TMD appears to influence the positioning of the extracellular and intracellular domains, affecting their relative orientation

• Studies suggest the TMD helps maintain the correct helical register between receptor components

Coimmunoprecipitation experiments with wild-type GHR and various mutants (including GHR-H150D, a dimerization interface mutant) demonstrated that the extracellular "dimerization interface" region is more critical for receptor predimerization than the TMD .

How does JAK2 association affect GHR stability and signaling?

JAK2 association with GHR has significant effects on receptor stability and function:

• Enhanced surface GHR levels through:

  • Increased efficiency of receptor biogenesis

  • Improved stability of mature receptors (extending half-life from ~1.5h to >4h)

• Requirements for JAK2-mediated GHR stabilization:

  • Intact Box 1 element in GHR (deletion abolishes stabilization)

  • Functional FERM domain in JAK2 (JAK2Δ1-47 mutant cannot stabilize GHR)

  • The pseudokinase and kinase domains are not required (JAK2 1-511-HA mutant maintains stabilization)

• JAK2's role in GH-induced ubiquitination:

  • GH-induced GHR ubiquitination occurs in cells with wild-type JAK2

  • This modification is absent in cells with kinase-deficient JAK2, contrary to some previous findings

These findings demonstrate that JAK2 plays dual roles in both stabilizing the receptor in the absence of ligand and mediating its down-regulation following GH stimulation.

How does the genetic architecture of response to r-hGH treatment align with the omnigenic model?

The genetic basis of r-hGH response appears to follow an omnigenic model, where:

• Multiple genes with small individual effects contribute to treatment outcomes

• Many associated genes are distant from core growth-related pathways

• The combined effect of these variants exceeds the predictive power of any single variant

Evidence supporting this model includes:

• GWAS studies identified variants weakly associated with response (including SOS1, INPPL1, ESR1, and PTPN1)

• Machine learning approaches identified associations with IGF2, GRB10, FOS, IGFBP3, and GHRHR in severe GHD

• Individual variants showed small effect sizes with limited predictive power

This complexity explains why traditional candidate gene approaches focusing on core growth pathways have yielded limited success. The omnigenic model suggests that genes with indirect connections to the core growth pathways exert substantial collective influence on treatment response.

How can transcriptomic data improve prediction of response to r-hGH therapy?

Transcriptomic approaches offer significant advantages over genetic variant analysis for predicting r-hGH response:

• Transcriptomic data captures the combined effect of multiple genetic variants

• It requires less adjustment for multiple testing, providing a greater signal window

• Network modeling can link genes with differential expression to the entire genomic background

Research findings:

• A set of genes was identified whose expression could classify therapeutic response in both GHD and TS patients with high accuracy (AUC > 0.9)

• The prediction model incorporated corrections for covariates including microarray batch, age, BMI, gender, and peak GH test response

• Of 58 genes with predictive expression values, 7 had previously identified genetic variants related to growth response

The condition-independent nature of these transcriptomic predictors is particularly notable, as they were effective in both GHD and TS despite their different genetic backgrounds and r-hGH dosing requirements.

How do developmental phenotype and environmental factors interact with genetic determinants of r-hGH response?

Response to r-hGH demonstrates complex interactions between genetic factors and developmental phenotype:

• Age-related effects:

  • Younger children generally show better response to r-hGH treatment

  • The blood transcriptome varies with developmental stages (infancy, childhood, puberty)

  • A tissue-independent transcriptomic signature corresponds to coordinated whole-body genetic programming for growth

• Key phenotypic interactions include:

  • Age at treatment initiation

  • Parental height

  • Body weight

  • Birth weight

• Interaction evidence:

  • GWAS studies using age and gender as covariates in minimally adjusted models showed different results compared to maximally adjusted models including growth phenotype covariates

  • This suggests genetic variants associated with r-hGH response interact with multiple growth-related phenotypes

These interactions likely explain why isolated genetic predictors often fail to capture the full complexity of treatment response, as they operate through effects in multiple tissues across different developmental stages.

What are the differences in r-hGH treatment efficacy between GHD and ISS patients?

A real-world study comparing r-hGH treatment efficacy in ISS and GHD patients found:

Despite differences in initial dosing, the treatment outcomes between ISS and GHD groups were largely similar, with both showing comparable improvements in growth parameters over time. The annual growth rate gradually decreased in both groups with extended treatment duration, but the difference between baseline HtSDS gradually increased .

How can pharmacogenomic approaches be applied to optimize r-hGH therapy in clinical practice?

Pharmacogenomic approaches offer potential strategies for personalized r-hGH therapy:

• Current challenges:

  • Individual genetic variants show small effect sizes

  • Clinical and auxological covariates significantly influence response

  • Complex interactions between genetics and developmental phenotype complicate prediction

• Promising approaches:

  • Transcriptomic prediction models incorporating network analysis

  • Combined genetic and phenotypic predictors

  • Machine learning algorithms integrating multiple data types

• Implementation considerations:

  • Controlling for relevant covariates (age, BMI, gender, peak GH)

  • Accounting for developmental stage

  • Considering condition-specific factors while leveraging condition-independent predictors

The emerging evidence suggests that transcriptomic data, particularly when analyzed through network models, may provide the most robust prediction of treatment response by capturing the complex genetic architecture underlying r-hGH response.

What evidence supports the efficacy of r-hGH in non-growth related applications such as burn treatment?

Clinical trials examining r-hGH for treating burns and donor sites found:

These findings suggest that r-hGH may be beneficial in large burns (>40% of total body surface area) where protein metabolism is altered. The mechanism appears to involve increased protein synthesis, counteracting the increased protein breakdown and decreased synthesis typically seen in severe burns .

The typical dosing for metabolic indications ranges from 0.1 to 0.2 mg/kg/day, and treatment duration can vary from days to one year. Modern depot formulations allow for less frequent administration (once or twice monthly) .

What experimental models and techniques are most effective for studying GHR signaling mechanisms?

Several experimental approaches have proven valuable for GHR research:

• Cell reconstitution systems:

  • Human fibrosarcoma cell lines with GHR and JAK2 reconstitution

  • Allow controlled analysis of specific receptor components

• Protein interaction assessment techniques:

  • Co-immunoprecipitation

  • Fluorescence/Förster Resonance Energy Transfer (FRET)

  • Bioluminescence Resonance Energy Transfer (BRET)

  • Fluorescence anisotropy

• Mutagenesis approaches:

  • Domain swapping (e.g., GHRLDLR with LDLR transmembrane domain)

  • Truncation mutants (e.g., JAK2 1-511-HA)

  • Point mutations (e.g., GHR-H150D dimerization interface mutant)

• Dynamic assessment methods:

  • Cycloheximide (CHX) chase experiments for receptor stability

  • Pulse-chase studies for trafficking kinetics

  • Endoglycosidase H sensitivity for monitoring maturation

These approaches have been critical in establishing key features of GHR biology, including preformed dimerization, activation mechanisms, and regulatory pathways.

How should researchers address the developmental context when designing r-hGH response studies?

Effective design of r-hGH response studies must account for developmental context:

• Critical covariates to control:

  • Age at treatment initiation

  • Body mass index (BMI)

  • Pubertal stage (Tanner stage)

  • Sex

  • Baseline growth hormone levels

• Statistical approaches:

  • Multiple regression models with relevant covariates

  • Stratification by developmental stage

  • Longitudinal analysis accounting for changing developmental status

• Transcriptomic considerations:

  • Blood transcriptome correction for age-related changes

  • Consideration of tissue-specific vs. tissue-independent signatures

  • Network analysis to identify developmental stage-specific patterns

The complex interactions between genetic factors and developmental phenotype necessitate careful study design to avoid confounding and identify true predictors of response.

What are the key methodological challenges in translating GHR research to clinical applications?

Several methodological challenges complicate translation of GHR research:

• Sample size limitations:

  • GHD is a rare disease, limiting statistical power for genetic studies

  • GWAS approaches require large cohorts rarely achievable in pediatric studies

• Heterogeneity issues:

  • Different etiologies within diagnostic categories (e.g., various causes of GHD)

  • Variable treatment protocols and monitoring practices

  • Different outcome measures across studies

• Technical considerations:

  • Transcriptomic analysis requires consideration of source tissue relevance

  • Network modeling approaches need validation across different populations

  • Integration of multiple data types presents computational challenges

• Clinical trial design:

  • Long treatment duration required for meaningful growth outcomes

  • Ethical considerations limit use of placebo controls in pediatric growth disorders

  • Growth assessment methodologies vary between centers